Thursday, January 14, 2021

PLGA from PolySciTech used in development of Gel-Microparticle Erlotinib delivery system for cancer therapy

 


Many therapeutic agents which are effective against cancer also have negative side effects in other parts of the body which leads to a need for a localized delivery system. Recently, researchers at University of California Los Angeles and Kangwon National University (Korea) used PLGA (AP045) from PolySciTech (www.polyscitech.com) to make ERT loaded microparticles for testing their cancer treatment potentials in a gel system. This research holds promise for improved cancer therapies. Read more: Lee, Song Yi, Mingyu Yang, Ji-Hye Seo, Da In Jeong, ChaeRim Hwang, Han-Jun Kim, Junmin Lee, KangJu Lee, JiHye Park, and Hyun-Jong Cho. "Serially pH-Modulated Hydrogels Based on Boronate Ester and Polydopamine Linkages for Local Cancer Therapy." ACS Applied Materials & Interfaces. https://pubs.acs.org/doi/abs/10.1021/acsami.0c16199

“Elaborately and serially pH-modulated hydrogels possessing optimized viscoelastic natures for short gelation time and single syringe injection were designed for peritumoral injection of an anticancer agent. Boronate ester bonds between phenylboronic acid (PBA) (installed in HA-PBA (HP)) and dopamine (included in HA-dopamine (HD)) along with self-polymerization of dopamine (via interactions between HD conjugates) were introduced as the main cross-linking strategies of a hyaluronic acid (HA) hydrogel. Considering pKa values (8.0–9.5) of PBA and dopamine, the pH of each polymer dispersion was controlled elaborately for injection through a single syringe, and the final pH was tuned nearby the physiological pH (pH 7.8). The shear-thinning behavior, self-healing property, and single syringe injectability of a designed hydrogel cross-linked nearby physiological pH may provide its convenient application to peritumoral injection and prolonged retention in local cancer therapy. Erlotinib (ERT) was encapsulated in a microsphere (MS), and it was further embedded in an HP/HD-based hydrogel for sustained and locoregional delivery. A rheologically tuned hydrogel containing an ERT MS exhibited superior tumor-suppressive efficiencies compared to the other groups in A549 tumor-bearing mice. A designed injectable hydrogel through a single syringe system may be efficiently applied to local cancer therapy with lower toxicities to healthy organs.”

No comments: